4 Results for "

systemic mastocytosis

" in MedChemExpress (MCE) Product Catalog:
Products (4)

4 Results for "systemic mastocytosis" in MCE Product Catalog:

1
1 Cited Publications
Cat. No.: HY-145557
CAS No.: 1616385-51-3
Purity:  98.81%
Synonyms: CGT9486; PLX 9486
Target:  

c-Kit

Research Areas:  

Cancer

Bezuclastinib (CGT9486) is an orally active, highly selective tyrosine kinase inhibitor with potent activity against KIT D816V. Bezuclastinib can be used for the research of nonadvanced systemic mastocytosis (NonAdvSM) .
loading...
    loading...
Cat. No.: HY-152839
CAS No.: 2505078-08-8
Purity:  98.68%
Synonyms: BLU-263
Target:  

c-Kit

Research Areas:  

Cancer

Elenestinib (BLU-263) is an orally active inhibitor of Tyrosine kinase with an IC50 value of 6 nM for KIT D816V. Elenestinib minimally penetrates the blood-brain barrier. Elenestinib can be used in the study of systemic mastocytosis .
loading...
    loading...
Cat. No.: HY-152839A
CAS No.: 2832013-93-9
Synonyms: BLU-263 phosphate
Target:  

c-Kit

Research Areas:  

Cancer

Elenestinib (BLU-263) phosphate is an orally active inhibitor of Tyrosine kinase with an IC50 of 0.2 nM for KIT D816V. Elenestinib phosphate minimally penetrates the blood-brain barrier. Elenestinib phosphate can be used in the study of systemic mastocytosis .
loading...
    loading...
Cat. No.: HY-107458
CAS No.: 834894-21-2
Target:  

c-Kit

Research Areas:  

Cancer

AP23848 is an ATP-dependent kinase inhibitor that effectively and selectively targets the Kit activation loop mutation both in vitro and in vivo, showing anti-tumor activity. AP23848 can inhibit the phosphorylation of the activated Kit mutation and tumor growth in mice, making it suitable for targeting diseases with the D816V mutation, such as systemic mastocytosis (SM) and acute myeloid leukemia (AML) research .
loading...
    loading...